# Lipika Goyal

Source: https://onco.cc/people/lipika-goyal/  
OnCo record `lipika-goyal` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Led the futibatinib trial and defined how FGFR2-driven bile duct cancers become resistant to targeted drugs.

## Summary

Lipika Goyal was principal investigator of FOENIX-CCA2, which won futibatinib approval for FGFR2 fusion-positive cholangiocarcinoma, and used serial ctDNA to describe the polyclonal FGFR2 kinase domain mutations that drive acquired resistance to FGFR inhibitors. She directs GI oncology at Stanford and leads trials of next-generation FGFR inhibitors.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: biliary; fgfr2; targeted-therapy
- Role: Associate Professor of Medicine and Director of Gastrointestinal Oncology, Stanford Cancer Institute
- Specialisms: Cholangiocarcinoma; FGFR2-targeted therapy; Acquired resistance; Circulating tumour DNA

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Goyal%20L%5BAuthor%5D%20FGFR2%20cholangiocarcinoma

## Connected records

- cancers: [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/)
- technologies: [Liquid biopsy (ctDNA)](https://onco.cc/technologies/liquid-biopsy/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- targets: [FGFR2](https://onco.cc/targets/fgfr2/)
- institutions: [Stanford Health Care / Stanford Cancer Institute](https://onco.cc/institutions/stanford/)
- trials: [FOENIX-CCA2](https://onco.cc/trials/foenix-cca2/)

---
JSON: https://onco.cc/api/v1/entities/lipika-goyal.json